Discover
ARCT
Arcturus Therapeutics Holdings Inc.
6.89
2 x 5.07
2 x 8.83
bid
ask
+
0.17
2.53%
2 @ 07:10 AM
7.30 +0.41 (5.95%)
| Ytd | 12.40% | |
| 1y | -46.96% |
6.74
day range
7.08
5.85
52 week range
24.17
| Open | 6.74 | Prev Close | 6.72 | Low | 6.74 | High | 7.08 | Mkt Cap | 195.83M |
| Vol | 413.72K | Avg Vol | 410.62K | EPS | -2.83 | P/E | N/A | Forward P/E | -7.41 |
| Beta | 2.64 | Short Ratio | 9.41 | Inst. Own | 90.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 7.71 | 200-d Avg | 9.34 | 1yr Est | 79.47 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.7 | -0.26 | 0.44 | 62.86% |
| 2024-08-05 | 2024-06 | -1.85 | -0.64 | 1.21 | 65.41% |
| 2024-05-08 | 2024-03 | -1.17 | -1 | 0.17 | 14.53% |
| 2024-03-07 | 2023-12 | -1.69 | -0.32 | 1.37 | 81.07% |
| 2023-11-14 | 2023-09 | -1.79 | -0.61 | 1.18 | 65.92% |
| 2023-08-07 | 2023-06 | 0.09 | -1.98 | -2.07 | -2300.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-16 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-12 | Leerink Partners | Upgrade | Outperform | |
| 2024-08-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-06 | Cantor Fitzgerald | Upgrade | Overweight |
Profile
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-13 | BARLOW JAMES F. | Director | 13.13K | Conversion of Exercise of derivative security |
| 2024-10-14 | CHIVUKULA PADMANABH | Chief Operating Officer | 435.33K | Sale |
| 2024-06-13 | FARRELL PETER CRAIG | Director | 98.70K | Conversion of Exercise of derivative security |
| 2024-06-13 | HOLMES EDWARD W. | Director | 3.13K | Conversion of Exercise of derivative security |
| 2023-07-13 | KUMMERFELD KEITH C | Officer | 950.00 | Sale |
| 2024-06-13 | MARANTZ JING L. | Director | 3.13K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Federated Hermes, Inc. | 4.69M | 77.59M | 17.33% |
| 2024-09-29 | Blackrock Inc. | 2.95M | 48.80M | 10.90% |
| 2024-09-29 | Nikko Asset Management Americas, Inc. | 2.32M | 38.27M | 8.55% |
| 2024-09-29 | Sumitomo Mitsui Trust Holdings, Inc. | 2.28M | 37.62M | 8.40% |
| 2024-09-29 | ARK Investment Management, LLC | 2.10M | 34.73M | 7.76% |
| 2024-09-29 | Vanguard Group Inc | 1.58M | 26.07M | 5.82% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Federated Hermes Kaufmann Fund | 2.44M | 40.27M | 8.99% |
| 2024-07-30 | Federated Hermes Kaufmann Small Cap Fund | 2.20M | 36.33M | 8.11% |
| 2024-10-30 | ARK ETF Tr-ARK Genomic Revolution ETF | 2.04M | 33.70M | 7.53% |
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 749.64K | 12.39M | 2.77% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 723.64K | 11.96M | 2.67% |
| 2024-10-30 | iShares Russell 2000 ETF | 593.78K | 9.82M | 2.19% |
Dividend
| Dividend | Date |
|---|---|
| 0.0085 | 2013-01-08 |
| 0.0085 | 2013-01-04 |
| 0.0086 | 2012-12-05 |
| 0.0086 | 2012-11-06 |
| 0.0086 | 2012-10-03 |
| 0.0086 | 2012-09-05 |
Split
| Split | Date |
|---|---|
| 1 : 7 | 2017-11-16 |